TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Debt-to-Equity

: -1.00 (As of Sep. 2016)

View and export this data going back to 2013. Start your Free Trial

TetraLogic Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. TetraLogic Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $30.81 Mil. TetraLogic Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2016 was $-30.94 Mil. TetraLogic Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2016 was -1.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TetraLogic Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

TLOG's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

TetraLogic Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for TetraLogic Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TetraLogic Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Debt-to-Equity

-0.07

0.82

-4.76

TetraLogic Pharmaceuticals Quarterly Data
	Dec11	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Debt-to-Equity															4.12	-4.76	-1.81	-1.35	-1.00

Competitive Comparison

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's Debt-to-Equity falls into.

TetraLogic Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TetraLogic Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	28.279)	/	-5.941
	=	-4.76

TetraLogic Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	30.809)	/	-30.938
	=	-1.00

TetraLogic Pharmaceuticals (OTCPK:TLOG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TetraLogic Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TetraLogic Pharmaceuticals Corp (OTCPK:TLOG) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Phoenixville Pike, Malvern, PA, USA, 19355

Website

http://www.tetralogicpharma.com

TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.

Executives

Hudson Bay Capital Management Lp	other: See Remarks	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Lazard Asset Management Llc	other: See Remarks	30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112
Nomura Holdings Inc	other: See Remarks	1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645
Whitebox Multi-strategy Partners Lp	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Pandora Select Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox General Partner Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416
Highbridge Capital Management Llc	other: See Remarks	277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Sander Gerber	other: See Remarks	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Whitebox Concentrated Convertible Arbitrage Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox Advisors Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416
Patrick Hutchison	officer: CFO & Treasurer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
Clarus Ventures Ii, Llc	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Ii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Ventures Ii Gp, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Nicholas Simon	10 percent owner	101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Headlines

No Headlines